Healthcare Providers and Services
Company Overview of Mayo Clinic
Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services in Minnesota, Florida, Arizona, Iowa, Georgia, and Wisconsin. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology and heart surgery. The company operates a network of care centers in the United States. It also provides medical education services through schools, offering various degree or certificate programs in continuing medical education, doctoral, master’s, and health sciences. In addition, the comp...
200 First Street SW
Rochester, MN 55905
Founded in 1919
Key Executives for Mayo Clinic
Chief Administrative Officer
Compensation as of Fiscal Year 2014.
Mayo Clinic Key Developments
GenomeDx Biosciences and Mayo Clinic Enter Agreement to Conduct Validation Study of Decipher Prostate Cancer Test in Patients Receiving Biopsy Prior to Treatment
Nov 11 14
GenomeDx Biosciences announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, for use in prostate biopsy specimens. The outcome of the study, if successful, is expected to support the application and utility of the Decipher test in patients receiving biopsy. The study is the result of research conducted by the Mayo Clinic Departments of Urology and Laboratory Medicine and Pathology. The study will be managed by Mayo Validation Support Services, which will serve as the collaboration liaison for the Mayo investigators while facilitating access to Mayo Clinic biospecimen resources and clinical information. GenomeDx and Mayo Clinic previously expanded their agreement in April 2013 to include an exclusive license to certain co-developed and Mayo-developed intellectual property. This new agreement includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer term follow-up and evaluation of biomarkers. The initial collaboration, entered in 2009, led to the development, validation, and commercialization of the Decipher Prostate Cancer Classifier for use in high-risk men following radical prostatectomy (prostate surgery). Decipher has already been validated in 10 peer-reviewed published studies, all work that was initiated with that initial Mayo collaboration. GenomeDx and Mayo Clinic previously expanded their agreement in April 2013 to include an exclusive license to certain co-developed and Mayo-developed intellectual property. This new agreement includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer term follow-up and evaluation of biomarkers. The initial collaboration, entered in 2009, led to the development, validation, and commercialization of the Decipher Prostate Cancer Classifier for use in high-risk men following radical prostatectomy (prostate surgery). Decipher has already been validated in 10 peer-reviewed published studies, all work that was initiated with that initial Mayo collaboration.
Cardio3 BioSciences Signs Preferred Access Agreement with Mayo Clinic
Oct 8 14
Cardio3 BioSciences announced the signing of a preferred access agreement with Mayo Clinic. Under this agreement, Mayo grants Cardio3 BioSciences preferred access to technologies developed in the Mayo Clinic Center for Regenerative Medicine, as well as select other Mayo technologies. This agreement is an expansion of a long-standing collaboration, which led to the development of C-Cure(R); Cardio3 BioSciences' product candidate now in advanced clinical trial testing (Phase III); an innovative cell therapy based on the discovery of the cardiopoiesis platform by the team of Andre Terzic, M.D., Ph.D. at Mayo Clinic. With this agreement, Mayo Clinic and Cardio3 BioSciences' unique expertise and competences will come together to accelerate innovative medical advancements to benefit patients. Mayo Clinic will significantly expand its ability to address unmet needs and Cardio3 BioSciences gains access to a broad portfolio in multiple areas such as cardiology, oncology or others, enabling the company to advance regenerative medicine's potential.
Second Genome, Inc. and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases
Oct 7 14
Second Genome, Inc. announced that it has entered into an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer. Under the terms of the agreement, the company will identify up to eight clinical indications where the microbiome has a potential role in disease and will collaborate on microbiome research with Mayo Clinic investigators who specialize in each of the designated disease areas. Mayo Clinic will provide human clinical samples from patients in targeted disease areas, and the company will deploy its proprietary microbiome discovery platform to identify biological pathways implicated in disease. Further, the company will utilize its platform to discover novel therapies that target these microbiome-mediated pathways. Mayo Clinic will make an equity investment in the company as part of the collaboration. Financial details were not disclosed. This collaboration enables the company to access Mayo Clinic's clinical and research expertise in retrospective and prospective studies across a range of diseases. It specifically strengthens the company’s current drug discovery programs in inflammatory bowel disease and metabolic disease, while supporting the company's move into new areas such as colorectal cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions